A new discovery has shed new light on the crucial role of the CD47 protein in bone fracture healing. Scientists have identified CD47 as an essential ...

Just a week after dropping the development of its CD47-targeting antibody magrolimab in blood cancers, Gilead Sciences has paused enrolment in clinical trials of the drug in solid tumours ...

Other studies of the CD47-directed antibody in large B cell lymphoma, multiple myeloma and solid tumours are not affected as they don't include azacitidine as a study drug. "While no clear trend ...

CD47-amyloid-β-CD74 signaling is a key driver of adaptive immunosuppression in sepsis, suppressing B cells and impairing ...

ImmuneOnco allocated a chunk of the money for the development and planned launch of IMM2520, a CD47×PD-L1 bispecific that it named as a key product. The biotech set aside a further 10% of its IPO ...

A new study from the USC Norris Comprehensive Cancer Center has found evidence that targeting CD47, a protein that is part of the innate immune system, could be a key step in fighting colorectal ...

Recent innovations include engineering CAR T-cells to overcome the immunosuppressive tumour microenvironment and enhancing ...

SIRPα interacts with CD47, a cell surface molecule often over-expressed on cancer cells. The CD47-SIRPα axis limits the antibody-mediated destruction of cancer cells through a ‘don’t eat me ...

In reality, however, only apoptotic cells are engulfed, apparently because their surface ligand CD47 is prevented from activating the inhibitory phagocyte receptor SIRPα. Figure 2: Formation of a ...

On the commercial front, Akeso's adjustments in drug pricing and optimization of its commercial systems led to new drug sales revenue surpassing RMB 2 billion in 2024, a 25% year-on-year increase. The ...

Target engagement increased in a dose-dependent manner, with CD47 receptor occupancy ranging up to 100% at the highest doses evaluated. ACC Abstract Details The poster presentation will be ...